This study shows that an abnormal karyotype is present in approximately one third of SMF and confers a more advanced clinical phenotype. Patients with monosomal karyotype have poor survival independently from the MYSEC-PM risk stratification and need to be identified. These findings reinforce the utility of assessing cytogenetics in SMF.

Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.

Mora B;Rumi E;Maffioli M;Cavalloni C;Merli M;Pietra D;Cazzola M;
2018-01-01

Abstract

This study shows that an abnormal karyotype is present in approximately one third of SMF and confers a more advanced clinical phenotype. Patients with monosomal karyotype have poor survival independently from the MYSEC-PM risk stratification and need to be identified. These findings reinforce the utility of assessing cytogenetics in SMF.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/1321787
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 28
social impact